Extended Data Figure 2. Pharmacological inhibition of EZH2 changes response of cells to TopoII inhibitors a.

Western Blot for EZH2 and H3K27me3 was performed on whole cell extracts after administration of 1μM DZNep for 4 days, 10μM GSK126 for 4 days, 2μM GSK126 for 9 days, or vehicle. Total Histone H3 is shown as a loading control. b, The fold change in etoposide IC₅₀ +/− s.e.m. in response to DZNep is plotted, n=3 biological replicates for H1975, H2030, HCC4006, A549, HCC2450, Calu1, H1650, H522, H2126, H1299, HCC15, H322, H2009, HCC95, H520, H460, Calu3, H2122, H23 and H3255, n=4 biological replicates for PC9, H157, HCC827, Sw1573, Calu6 and H441, * P<0.02. Cell lines with mutations in BRG1 or EGFR are indicated. Note that the H23 cell line has a very late coding region mutation in BRG1 (K1533N) and is predicted to produce functional protein²², consistent with its protected phenotype in our assays. c, Average fold change +/− s.e.m. between vehicle treated and indicated EZH2i treated lines for etoposide IC₅₀ is graphed, n=3 biological replicates, * P<0.03, ** P<0.01. d, Fold change in doxorubicin IC₅₀ in response to DZNep, n=2 biological replicates.